Immatics N.V.
corporate_fare Company Profile
Immatics N.V. (NASDAQ:IMTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for IMTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-26, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for IMTX spans 6-K, 4, SCHEDULE 13D/A.
Recent high-impact activity:
- Immatics ESMO Data: IMA402 32% cORR in PRAME-High Melanoma, IMA203CD8 55% cORR in Gynecologic Cancers
- Immatics PRAME Programs Show 32% and 41% Response Rates in Early Solid-Tumor Trials
- Immatics' IMA203CD8 Achieves 51% ORR Across Solid Tumors and 60% in Gynecologic Cancers
- Perceptive Advisors Buys $7.5M of Immatics Shares at $8.69
- Perceptive Advisors Discloses 7.6% Stake in Immatics After $7.5M Offering Purchase
Financial Snapshot
Short Interest & Short Volume
3.73 days to coverFINRA reported short interest of 3,747,677 shares in IMTX as of the October 15, 2026 settlement, a 1.6% increase from the prior period — about 3.7 days to cover at its recent average daily volume. On October 30, 2026, 50.1% of IMTX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
IMTX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.